TLDR: Indegene, a digital-first life sciences commercialization company, has launched its NEXT Medical Writing Automation platform. This advanced AI-powered solution, leveraging generative AI and Indegene’s proprietary Cortex engine, aims to significantly streamline the creation of high-quality, regulatory-compliant documents across clinical development and regulatory submissions, addressing critical industry challenges.
Bangalore, India – July 14, 2025 – Indegene, a leading digital-first life sciences commercialization company, today announced the official launch of its groundbreaking NEXT Medical Writing Automation platform. This innovative solution is poised to redefine the landscape of medical writing by integrating advanced generative artificial intelligence (GenAI) capabilities to accelerate the production of high-quality, regulatory-compliant documents essential for clinical development and regulatory submissions.
The life sciences sector has long grappled with immense pressure on medical writing teams, who are tasked with delivering precise, regulatory-ready content under stringent timelines. These challenges are often compounded by fragmented data and constantly evolving compliance demands. The NEXT Medical Writing Automation platform directly addresses these pain points by combining Indegene’s extensive decades of medical writing expertise with cutting-edge GenAI technology and its proprietary AI engine, Cortex.
Cortex, Indegene’s specialized knowledge engineering platform for life sciences, provides enterprise-grade governance, multi-agent orchestration, and seamless integration with sponsor formats and workflows. This powerful combination enables the NEXT platform to operate within familiar environments such as Microsoft Word, automatically generating compliant drafts while meticulously preserving traceability and format consistency. Furthermore, it integrates effortlessly with Regulatory Information Management (RIM) systems, facilitating effortless cross-document harmonization.
Key features of the NEXT Medical Writing Automation platform include automated scheduling, intelligent task assignment, integrated data flow, and a compliance-centric design. These functionalities are designed to significantly reduce document creation time, allowing medical writers to shift their focus from laborious manual formatting to more strategic insights and critical thinking.
Sameer Lal, SVP, Enterprise Medical Solutions at Indegene, emphasized the transformative potential of the new platform, stating, “We see this platform as more than automation — it’s about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”
Also Read:
- CellBot Revolutionizes Medical Research with AI on CellVerse Platform
- MATH Group Unveils Advanced AI Platform for Enterprise Transformation
This strategic launch further strengthens Indegene’s global offerings, building upon its 2024 acquisition of Trilogy Writing & Consulting GmbH, a prominent global medical writing firm. The introduction of NEXT Medical Writing Automation underscores Indegene’s unwavering commitment to developing AI-driven, domain-first solutions that empower life sciences organizations to modernize critical processes and confidently achieve their business objectives.
